

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

-----  
FORM 8-K  
-----

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

February 4, 1999

000-27078

-----  
Date of Report (Date of earliest  
event reported)

-----  
(Commission File Number)

HENRY SCHEIN, INC.  
(Exact name of registrant as specified in its charter)

Delaware

11-3136595

-----  
(State or other jurisdiction of  
incorporation or organization)

-----  
(I.R.S. Employer Identification Number)

135 Duryea Road, Melville, NY 11747

-----  
(Address of Principal Executive Offices) (Zip Code)

(516) 843-5500

-----  
(Registrant's telephone number, including area code)

=====

ITEM 5. OTHER EVENTS.

On February 4, 1999, Henry Schein, Inc. issued the press release filed as an Exhibit to this Current Report on Form 8-K with respect to the voluntary recall of dental anesthetic products by its unconsolidated affiliate, Novocol Pharmaceutical of Canada, Inc.

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

(a) Not applicable.

(b) Not applicable.

(c) Exhibits:

99.1 Press Release, dated February 4, 1999.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, Henry Schein, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HENRY SCHEIN, INC.

By: /s/ Michael Ettinger

-----  
Name: Michael Ettinger  
Title: Vice President and  
Associate General Counsel

Date: February 5, 1999

EXHIBIT INDEX

DOC. NO.

DOCUMENT DESCRIPTION

99.1

Press Release, dated February 3, 1999.

[Henry Schein Letterhead]

FOR: Henry Schein, Inc.  
CONTACT: Steven Paladino  
Senior Vice President and  
Chief Financial Officer  
(516) 843-5500

Susan Vassallo  
Manager, Investor  
and Public Relations  
(516) 843-5562  
svassa@henryschein.com

FOR IMMEDIATE RELEASE

Investor Relations:  
Robert P. Jones/Jill Ruja  
Press: Stacy Berns  
Morgen-Walke Associates  
(212) 850-5600

HENRY SCHEIN COMMENTS ON MANUFACTURER'S PRODUCT RECALL

Melville, NY - February 4, 1999 -- Henry Schein, Inc. (Nasdaq:HSIC) reported today that Novocol Pharmaceutical of Canada, Inc., (Novocol), an affiliated company in which it owns a non-controlling interest, is conducting a further voluntary recall of its dental anesthetic products that began on January 11, 1999. This recall consists of approximately 230 batches sold by Novocol in 1997 and 1998 under its name and private labels. Novocol products are distributed in the United States by dental product dealers, including Henry Schein.

Novocol initiated the second recall as a result of discussions concluded today between Novocol and the United States Food and Drug Administration (FDA). Novocol has advised Henry Schein that it is cooperating with the FDA to resolve the issues that led to the recalls as quickly as possible, however, it is unable to estimate how long this will take. Pending such resolution, Novocol has suspended production of the products. As previously reported, the FDA has raised questions regarding Novocol's compliance with current Good Manufacturing Practices (cGMP's).

Henry Schein has previously reported that its equity in earnings of this unconsolidated affiliate is estimated at \$1.6 million for 1998. In addition, Novocol products represent approximately \$15 million of Henry Schein's estimated sales for 1998, or less than one percent of 1998 sales. Henry Schein is currently in the process of determining the potential financial impact of this matter on its equity and sales, as well as recall costs as a distributor.

Henry Schein, Inc. is the largest distributor of healthcare products and services to office-based healthcare practitioners, including dental practices and laboratories, physician practices and veterinary clinics. The Company, recognized for its excellent customer service and low prices, serves more than 250,000 customers worldwide. Henry Schein's world headquarters are in Melville, N.Y. For more information, visit the Henry Schein website at <http://www.henryschein.com>.

Certain information contained herein includes information that is forward looking. The matters referred to in forward looking statements may be affected by the risks and uncertainties involved in the Company's business. The forward looking statements are qualified in their entirety by the cautionary statements contained in the Company's Securities and Exchange Commission filings.

###